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Abstract
Background: Killed oral cholera vaccines (OCVs) are available but not used routinely for cholera control except in Vietnam,
which produces its own vaccine. In 2007–2008, unprecedented cholera outbreaks occurred in the capital, Hanoi, prompting
immunization in two districts. In an outbreak investigation, we assessed the effectiveness of killed OCV use after a cholera
outbreak began.
Methodology/Principal Findings: From 16 to 28 January 2008, vaccination campaigns with the Vietnamese killed OCV were
held in two districts of Hanoi. No cholera cases were detected from 5 February to 4 March 2008, after which cases were
again identified. Beginning 8 April 2008, residents of four districts of Hanoi admitted to one of five hospitals for acute
diarrhea with onset after 5 March 2008 were recruited for a matched, hospital-based, case-control outbreak investigation.
Cases were matched by hospital, admission date, district, gender, and age to controls admitted for non-diarrheal conditions.
Subjects from the two vaccinated districts were evaluated to determine vaccine effectiveness. 54 case-control pairs from the
vaccinated districts were included in the analysis. There were 8 (15%) and 16 (30%) vaccine recipients among cases and
controls, respectively. The vaccine was 76% protective against cholera in this setting (95% CI 5% to 94%, P=0.042) after
adjusting for intake of dog meat or raw vegetables and not drinking boiled or bottled water most of the time.
Conclusions/Significance: This is the first study to explore the effectiveness of the reactive use of killed OCVs during a
cholera outbreak. Our findings suggest that killed OCVs may have a role in controlling cholera outbreaks.
Citation: Anh DD, Lopez AL, Thiem VD, Grahek SL, Duong TN, et al. (2011) Use of Oral Cholera Vaccines in an Outbreak in Vietnam: A Case Control Study. PLoS
Negl Trop Dis 5(1): e1006. doi:10.1371/journal.pntd.0001006
Editor: Edward Ryan, Massachusetts General Hospital, United States
Received October 19, 2010; Accepted December 22, 2010; Published January 25, 2011
Copyright:  2011 Anh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Bill and Melinda Gates Foundation (http://www.gatesfoundation.org) provided financial support through the Cholera Vaccine Initiative (CHOVI)
program, administered by the International Vaccine Institute (IVI), Seoul, Republic of Korea. Current donors providing unrestricted support to the IVI include the
Governments of Kuwait, Republic of Korea, and Sweden. The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: annalenalopez@hotmail.com
¤ Current address: Pfizer, Wanchai, Hong Kong, Special Administrative Region, People’s Republic of China
Introduction
Cholera is increasingly being reported, and more countries are
now experiencing outbreaks [1], some lasting for several months.
In 2001, the World Health Organization (WHO) recommended
the use of oral cholera vaccines (OCV) in populations at risk in
endemic areas but not reactively once an outbreak has begun [2].
While this recommendation has been updated in March 2010, to
include reactive use of these vaccines [3], OCVs have only been
used for reactive cholera control in 2000, when a live attenuated
OCV (CVD-103HgR) was used in an outbreak in Micronesia [4].
The CVD-103HgR was assessed to be effective in this outbreak,
although this was an observational study. In contrast, CVD-
103HgR conferred no protection in the only randomized
controlled efficacy trial of this vaccine [5], and this vaccine is
no longer manufactured. There is one internationally licensed
killed oral cholera vaccine, the recombinant B subunit killed
OCV (rBS-WC, Dukoral, Crucell/SBL), but it has not been
routinely adopted for public health use due to its high cost,
limited duration of protection and logistic issues with vaccine
administration. A variant of this oral vaccine, containing only
killed whole cells (Vibrio cholerae O1 and O139) is manufactured in
Vietnam following technology transfer from Swedish scientists.
Vietnam is the only country in the world to use an OCV in its
public health system for cholera control. Since 1997, this killed
OCV (ORC-Vax) has been licensed and produced locally by the
Company for Vaccine and Biological Production (VaBiotech) in
Hanoi. The vaccine was found to confer 66% protection against
an El Tor cholera outbreak occurring eight months following
vaccination among all individuals aged 1 year and older [6] and
50% protection, three to five years after vaccination [7]. It is safe,
inexpensive, and easy to administer [8]. Packaged in five-dose
vials, each 1.5 ml liquid vaccine dose is drawn and squirted into
the mouth by a syringe without a needle. Each dose contained:
5.0610
10 formalin-killed V. cholerae Inaba, El Tor strain Phil
6973; 2.5610
10 heat-killed V. cholerae Ogawa, classical strain
Cairo 50; 2.5610
10 formalin-killed V. cholerae Inaba, classical
strain 569B; and 5.0610
10 formalin-killed V. cholerae O139 strain
4260B. After oral administration, individuals are asked to drink
water, but no oral buffer is required. Given in two doses, one to
www.plosntds.org 1 January 2011 | Volume 5 | Issue 1 | e1006four weeks apart, it may be given to individuals aged one year
and older.
Since the seventh pandemic reached Vietnam in 1964, cholera
has been reported annually. A review of reported cases to the
National Institute of Hygiene and Epidemiology (NIHE) from
1991 to 2001 showed that cholera is endemic in the central and
southern provinces [9]. Compared with shigellosis and typhoid
fever, cholera cases have decreased dramatically in 1997 to 2001.
This decrease in cholera cases has been partly attributed to the
extensive use of the killed OCV in Vietnam [10].
From 1997 to 2005, 9.2 million doses of the killed OCV have
been used in the Expanded Programme of Immunization (EPI) of
20 cholera endemic provinces and metropolitan areas in Vietnam,
mostly located in the central and southern areas (Figure 1).
Vaccines are routinely provided in the endemic areas through
regular monthly immunization sessions. In the routine EPI setting,
depending on the commune, eligible children, aged 2–5 years are
gathered for immunization on the same days for cholera
vaccination. OCVs are provided 2 to 4 weeks apart. The killed
OCV is also used preemptively in mass campaigns whenever an
increase in the number of culture-confirmed cases are reported.
National diarrheal disease surveillance is performed routinely and
culture confirmation of organisms is available at the 61 provincial
Centers for Preventive Medicine and in the national and four
regional Institutes of Hygiene and Epidemiology. When cholera
cases are detected in known endemic areas, mass vaccinations are
arranged in designated locations such as schools, commune and
district health facilities or government offices in the affected areas.
In October 2007, an increase in acute watery diarrhea cases was
reported in Hanoi, caused by genetically altered Vibrio cholerae O1
Ogawa biotype El Tor producing classical biotype cholera toxin.
Prior to this outbreak, the strain had never been isolated in Vietnam
[11]. From 24 October to 4 December 2007, nearly 2,000 diarrhea
cases were reported from Hanoi and neighboring provinces, of
which 295 were laboratory confirmed. In response the Ministry of
Health of Vietnam mandated the provision of free medical
treatment for anyone suffering from acute diarrheal illness.
New cholera cases were identified on 24 December 2007 from
Hanoi, thus, in the first week of January 2008, just prior to the
Vietnamese Tet New Year, a decision was made to immunize two
particularly hardhit districts of Hanoi – Hoang MaiandThanh Xuan
(combined population of ,462,570). These districts are located close
to waterways into which sewage drains. The Vietnam National
Institute of Hygiene and Epidemiology (NIHE) together with the
Ministry of Health launched the mass vaccination campaign on 16–
28 January 2008, providing two doses of the killed oral cholera
vaccine, spaced one week apart. Because of the absence of cases
detected during the outbreak among children less than 10 years of
age, vaccines were only provided to residents aged 10 years and older.
Pregnant residents were also not eligible for vaccination. The
campaign was announced in newspapers and radio and eligible
residents were invited to proceed to commune health centers.
Vaccination cards were provided to vaccinees and logbooks
containing the names of vaccine recipients were maintained. It was
estimated that ,80% of the estimated 370,000 age-eligible individuals
received one or more doses of the killed OCV. In addition,
educational health campaigns were also conducted to inform the
public of the signs of illness and to improve sanitary practices.
From 24 December 2007 to 6 February 2008, 59 diarrhea cases
(33 culture confirmed V. cholerae O1) were identified, all cases
coming from Hanoi. No cases were detected until 5 March 2008,
when the number of diarrhea cases increased and V. cholerae O1
Ogawa was again identified as the causative agent. The NIHE
requested the International Vaccine Institute (IVI) to assist in the
outbreak investigation, specifically looking into the role of vaccines
for control. This provided a unique opportunity to assess the
effectiveness of reactive oral cholera vaccination in a cholera
outbreak, as there has been little experience in the use of OCVs in
cholera epidemics. Figure 2 shows the clinical cholera cases in
Hanoi from 24 October 2007 to 15 July 2008.
Figure 1. Map of Vietnam indicating cholera endemic areas in
the Central coastal regions and in the South where cholera
vaccines were used from 1997 to 2005.
doi:10.1371/journal.pntd.0001006.g001
Author Summary
Simple measures such as adequate sanitation and clean
water stops the spread of cholera; however, in areas where
these are not available, cholera spreads quickly and may
lead to death in a few hours if treatment is not initiated
immediately. The use of life-saving rehydration therapy is
the mainstay in cholera control, however, the rapidity of
the disease and the limited access to appropriate
healthcare units in far-flung areas together result in an
unacceptable number of deaths. The WHO has recom-
mended the use of oral cholera vaccines as a preventive
measure against cholera outbreaks since 2001, but this
was recently updated so that vaccine use may also be
considered once a cholera outbreak has begun. The
findings from this study suggest that reactive use of killed
oral cholera vaccines provides protection against the
disease and may be a potential tool in times of outbreaks.
Further studies must be conducted to confirm these
findings.
Cholera Vaccines in Outbreak in Vietnam
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A matched, hospital-based, case-control investigation was con-
ducted from 8 April to 10 June, 2008. Hanoi has nine urban districts
with a population of ,2.9 million [12]. Hospitalized patients from
the two vaccinated districts - Hoang Mai and Thanh Xuan, as well
as the unvaccinated districts - Dong Da and Cau Giay were invited
to participate in the outbreak investigation (Figure 3). These districts
have a combined population of ,1 million [12]. These districts have
similar population characteristics, environmental conditions and
epidemiological data from past cholera outbreaks. Residents of these
districts are also served in common and have equal chances of
attending five hospitals including the National Institute of Infectious
and Tropical Disease (NIID) Hospital, Bach Mai District Hospital,
Saint Paul Hospital, Dong Da District Hospital and Transportation
Hospital. Case and control exposure histories of subjects from
Hoang Mai and Thanh Xuan , were compared for evaluation of risk
factors and effectiveness of killed OCV use during the outbreak, the
results of which are presented here.
Participants: Selection of Cases
Patient admission logbooks at the five hospitals were reviewed
daily to identify patients admitted for diarrhea. Hospital records of
identified patients were then reviewed. Patients who met the
clinical case definition for cholera were invited to participate. A
cholera case was defined, a priori, as being hospitalized for
diarrhea with illness onset of 8 April to 20 May 2008, with
diarrhea defined as 3 or more loose, liquid or watery bowel
movements in any 24 hour period; were 10 years of age or older
and a resident of any of the 4 districts of interest. Cases were
identified without knowledge of the vaccination status.
Participants: Selection of Controls
One matched control per case was recruited from wards of the
same hospital, except for cases admitted to NIID, wherein controls
were identified from the trauma and surgical wards of Bach Mai
Hospital, an adjacent general hospital. Patient admission logbooks
were reviewed to identify controls hospitalized for non-diarrheal
conditions. Controls were matched for each case by the date of
presentation (65 days), age group (10–20 years old, 21–40 years old,
40+ years old), gender and district of residence. The first control in
the logbook that fulfilled the matching characteristics to the case was
identified and invited to participate. Controls were chosen by
reviewers who were unaware of the vaccination status of the patients.
Data Collection Procedures
Data were obtained through transcription of clinical records
and subject interviews using a standardized questionnaire.
Figure 2. Clinical cholera cases in Hanoi, 2007 to 2008.
doi:10.1371/journal.pntd.0001006.g002
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(tap water, public well), behavioral characteristic such as hand
washing and sanitation (toilet with flush, latrine, none), as well as
exposure factors (intake of raw vegetables, dog meat, shrimp paste;
not drinking boiled or bottled water), were collected. Vaccination
status including the number and date of dosing was verbally
ascertained based on subject recall. When available the reported
dosing dates were cross-checked against a vaccination card. In
order to evaluate the use of the OCV in this outbreak setting we
defined ‘‘vaccinated’’ a priori as receipt of one or two doses of
OCV from 16–28 January 2008 without further consideration to
dosing interval or interval between vaccination and date of
selection into the study. Microbiological culture results, completed
by and according to the standard operating procedures of the
admitting hospital laboratory, were also obtained during the study
when available.
Statistical Methods
To detect 50% vaccine protection, we assumed the following:
40% of controls would be vaccinated; the correlation of vaccine
histories among matched cases and controls, phi, was .05; and with
80% power at P,.05 (2-tailed), at least 172 cases and 172 controls
were required for the investigation.
Characteristics and exposures of hospitalized cases and controls
from the vaccinated and unvaccinated districts were compared. To
assess the effect of vaccination, we included diarrheal cases and
controls hospitalized for non-diarrheal causes from the vaccinated
districts. Baseline characteristics were statistically compared using
McNemar’s test for dichotomous variables and the paired Student
t-test for continuous variables. Only complete pairs in which both
the case and the control had exposure measurements were
included, and the information contained in the incomplete pairs
was ignored. The adjusted matched odds ratio (OR) and 95%
confidence interval (CI) for calculation of vaccine effectiveness was
determined using multivariate conditional logistic regression [13].
Statistical analysis was planned at the outset, to include all
variables with p,0.05 in univariate analysis and the primary
variable of interest (vaccination status) in the multivariable model.
Vaccine effectiveness was calculated as: (1-matched OR)6100. All
p values and 95% confidence intervals, estimated from the point
estimates and standard errors for the coefficient for the vaccination
variable in the models, were interpreted in a two- tailed manner.
Statistical significance was designated as a p value,0.05. All
statistical analyses were performed using Stata10 (StataCorp,
College Station, TX).
Ethics
The study qualified for exemption from review by the IVI
Institutional Review Board and Ethical Review Committee of
NIHE as the study was conducted as part of an outbreak
investigation establishing risk factors and modifiers. Verbal
consent was obtained in lieu of written consent from both cases
and controls as the project was conducted as part of an outbreak
investigation. Consent was documented in a logbook.
Results
We enrolled 126 matched pairs of cases and controls for the
outbreak investigation; one matched pair was excluded when on
review the case definition was not met by the case (Figure 4). After
exclusion of this matched pair, among cases, the ages ranged from
17 to 86 years old while the control age range was 15 to 80 years
old. Thirty-seven percent of cases had vomiting and 76% had
some or severe dehydration on admission. Among those with
severe dehydration, only one was vaccinated. Of the 99 cases
whose stools were tested, 74 subjects had culture confirmed V.
cholerae O1 (75%). Only one vaccine recipient had culture
confirmed cholera. Table 1 shows the causes of hospitalization
for the controls.
Of the 125 matched pairs, 54 pairs (43%) were residents of
districts where the mass vaccination campaign was carried out and
were included in this evaluation of vaccine effectiveness. We
compared the baseline characteristics of cases and controls from
Huang Mai and Thanh Xuan, where the mass vaccination
campaigns were carried out, and found no significant differences
in demographic and socio-economic characteristics (Table 2). On
comparing the exposure of cases with controls, intake of raw
vegetables and not drinking boiled or bottled water were found to
be significantly different (p,0.05). Similar results were obtained
when comparing all cases and controls in the outbreak
investigation, including patients from both the vaccinated and
unvaccinated districts (data not shown). Because dog meat is
customarily eaten with raw vegetables and 70% of those who ate
dog meat also ate raw vegetables, we decided to combine these in
the multivariate regression model.
Figure 3. Urban districts of Hanoi showing Hoang Mai and Thanh Xuan, where mass vaccination campaigns were held in January
2008, and Dong Da and Cau Giay, the unvaccinated districts included in the study.
doi:10.1371/journal.pntd.0001006.g003
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and 16 of 54 controls (30%) were classified as vaccinated, having
received at least one dose of the killed OCV from 16–28 January
2008. Seventy-five percent (6/8) of vaccinated cases and 63% of
vaccinated controls (10/16) received two doses of killed OCV
during the vaccination campaign. The unadjusted vaccine
effectiveness (VE) was 54% (95% CI 231% to 84%; p-
value=0.144), however, after adjusting for factors which were
found to be significantly associated with being a cholera case at
P,0.05 in univariate analyses (intake of dog meat or raw
vegetables and not drinking boiled or bottled water most of the
time) (Table 3), the killed OCV was found to have an effectiveness
of 76% (95% CI 5% to 94%, p=0.04).
Discussion
This is the first study to report on the use of killed OCV in an
outbreak situation. While a significant association was detected
between receipt of at least one dose of the killed OCV and
protection against cholera, our study has several limitations.
Potential Limitations
Because there may be inherent differences in health care
utilization and knowledge among those who presented for
vaccination and those who refused vaccination [14,15], bias may
have been introduced in our assessment for vaccine protection,
and may have exaggerated our results. The protective effect may
have been augmented, as it has been shown that people refusing
participation are more likely to engage in high-risk behaviors as
compared to vaccines [15]. However, there were no differences in
the baseline demographic, socioeconomic and exposure charac-
teristics of vaccinated and non-vaccinated cases and controls.
Moreover, there were several factors that may have decreased the
true protective effect of the vaccine during this outbreak, namely:
(1) individuals with a recent history of cholera-like diarrhea may
not have participated in the campaign and were included in the
control group (2) recipients of a single dose of the vaccine were
included in the analysis (3) vaccinees may have been more likely to
use the treatment centers for the care of diarrhea compared to
refusers. A comparison of a partially immunized vaccine group to
a control group with varying levels of natural immunity would
tend to depress apparent vaccine protection against subsequent
cholera.
Our evaluation was also limited by use of a clinical case
definition without culture confirmation, however we used a strict
case definition and random cases were culture confirmed.
Moreover, inclusion of non-culture confirmed cases, if ever, would
have depressed the protection afforded by vaccination as some
cases may not be due to V. cholerae.
We did not reach the sample size required (54 instead of the
desired 172) because of difficulty enrolling controls during this
outbreak, throughout which most hospital beds were occupied by
cholera cases. The smaller sample size may explain the unadjusted
VE as being not statistically significant. We tried to limit selection
bias by enrolling cases and controls without prior knowledge of
their vaccination status. Moreover, in order to prevent interview-
ers from overzealously eliciting vaccination history, several
exposure questions were included in the questionnaire.
Lastly, our study was initiated more than two months after the
campaign, thus we were unable to include cases proximate to
vaccination, however since the outbreak was prolonged and
recurrent and vaccine effectiveness lasts for three to five years [7],
measurement of the effectiveness of OCV use in this setting was
still warranted.
Implications for the Control of Cholera
To our knowledge, this is the first study that explored the
reactive use of a killed OCV in an outbreak. In Hanoi, the
outbreak was described as having occurred in three waves, each
separated by 14 to 26 day intervals with no recorded cases in
between each wave. Vaccination was performed while the second
wave was ongoing (see Figure 3). Since the mass vaccination
campaign was performed in the two districts that have been most
affected in the previous waves of diarrheal cases, the characteristics
of the residents in these districts may have been different from
other areas that make them vulnerable to diarrheal outbreaks and
may be more amenable to district specific interventions. However,
comparison of baseline characteristics and exposures of patients
Figure 4. Flowchart of cases and controls in the study.
doi:10.1371/journal.pntd.0001006.g004
Table 1. Cause of hospitalization among controls.
Cause of hospitalization
* No. of controls (n=125)
Respiratory 32
Dental Problem 21
Dengue, viral or unspecified febrile disease 19
Gastrointestinal 10
Neurological 10
Cardiovascular 9
Urogenital 5
Endocrine 3
Musculoskeletal Trauma 3
Skin / Soft Tissue Problem 2
Other
{ 11
*No controls were admitted for or experienced diarrhea during hospitalization.
{Alcoholism, cancer, unspecified non-infectious condition.
doi:10.1371/journal.pntd.0001006.t001
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unvaccinated districts (Dong Da and Cau Giay) showed no
statistically significant differences (data not shown).
In the recently updated WHO recommendations, consideration
for both preemptive and reactive use of OCVs is supported after
assessment of local infrastructure and epidemiology. A model of a
refugee camp based cholera outbreak in Africa compared the cost-
effectiveness of several cholera controls strategies, including
establishment of treatment centers and reactive vaccination. Based
on duration of the hypothetical outbreak and the size of the
hypothetical camp, reactive vaccination will only be a cost-
effective option if the price of the vaccine falls below $0.22 per
dose [16]. However, there were several limitations to this analysis
[17] and this study did not account for large prolonged outbreaks
such as those seen recently in Zimbabwe [18,19], Angola [20,21]
and Vietnam [11], which would favor reactive vaccination.
Since 1996, extensive cholera outbreaks of this magnitude had
not been reported in Vietnam, especially in areas where the killed
OCV is routinely used. Between 5 March and 22 April 2008, the
Vietnamese Ministry of Health reported 2,490 cases of severe
acute watery diarrhea including 377 that were positive for V.
cholerae O1 Ogawa [22]. Twenty provinces in the northern areas
were affected in 2007 to 2008. No deaths were reported during
these outbreaks indicating good case management. On the other
hand, in Africa, cholera outbreaks are deadly. In Zimbabwe alone
from August 2008 to May 2009, almost 100,000 cases have been
identified with more than 4,000 deaths [18], 61% of whom did not
reach a health facility for treatment [19]. Similarly in Angola, an
outbreak from February to June 2006 with 46,758 cases and 1,893
deaths [20,21] were reported with case fatality rates in some
provinces tragically reaching up to 30% [20]. Provisions for clean
water, adequate sanitation and good case management are
necessary for controlling cholera, however, these are unlikely to
happen in the near future in most of the developing world where
cholera continues to cause significant hardship and misery. New
measures need to be taken. Prior to the release of the March 2010
WHO position paper several groups were pressing for a rethink of
the WHO stand on vaccine use for outbreaks [23]. The results of
our study are consistent with earlier evaluations of the protective
effects of OCV [6]. Microbiologic studies have shown that the
outbreak was caused by the new strain of El Tor V. cholerae O1
producing classical cholera toxin [11]. This new strain has been
increasingly reported in Asia and in parts of Africa [24–26] with
some indications of increased severity [27]. The killed OCV
provided protection against this new strain suggesting that there
may be a role for reactive use of the killed OCV in future cholera
outbreaks.
The Vietnamese killed OCV has now been extensively modified
by the IVI to comply with WHO and current Good Manufac-
turing Practices (cGMP) standards. The modified vaccine was
recently licensed in Vietnam (mORC-VAX). In order to expand
its use internationally and to allow purchase by United Nations
Table 2. Characteristics of diarrheal cases compared with controls hospitalized for other conditions during a cholera outbreak in
Hanoi, Vietnam, 2008 (vaccinated districts).
Variable Discordant pairs (case exposed) Unadjusted matched odds ratio p-value
Mean age (years)*
{ 1.00 0.897
Mean monthly income (USD)
* 1.00 0.648
Male gender
{ 3 (1) 2.00 0.571
Occupation requiring frequent travel
{ 12 (9) 3.00 0.099
Ate dog meat
1 13 (10) 3.33 0.067
Ate raw vegetables
I 18 (14) 3.50 0.027
Ate dog meat or raw vegetables
" 21 (17) 4.25 0.009
Ate shrimp paste** 11 (6) 1.200 0.763
Do not drink boiled or bottled water most of the time
{{ 12 (11) 11.000 0.022
Live in household without safe water/household tap
{{ 6 (2) 0.500 0.423
*Modeled as continuous variable.
{Matching factor.
{Examples of occupations requiring little or no travel include homemakers, seamstresses and office workers, while examples of occupations requiring frequent travel
include laborers, car drivers and tour guides. Information available for 50 pairs, no missing information among discordant pairs.
1Information available for 53 pairs, no missing information among discordant pairs.
IInformation available for 53 pairs, no missing information among discordant pairs.
"Information available for 53 pairs, no missing information among discordant pairs.
**Information available for 53 pairs, no missing information among discordant pairs.
{{Information available for 52 pairs, no missing information among discordant pairs.
{{Information available for 52 pairs, no missing information among discordant pairs.
doi:10.1371/journal.pntd.0001006.t002
Table 3. Vaccine effectiveness against clinical cholera in
Huang Mai and Thanh Xuan following the mass vaccination
campaign in 2008 (vaccinated districts).
Controls
Vaccinated Unvaccinated Total
Cases Vaccinated 3 5 8
Unvaccinated 11 35 46
Total 14 40 54
Vaccinated was defined as having received one or two doses of vaccine.
Crude Protective Efficacy (PE)=54% (95% CI 231% to 84%; p-value=0.144).
Adjusted PE=76% (95% CI 5% to 94%; p-value=0.042).
Stepwise selection (P.0.05 for removal), candidate variables vaccination status
plus variables significant (P#0.05) in univariate analysis; dog meat or raw
vegetables, and not drinking bottled or boiled water most of the time.
doi:10.1371/journal.pntd.0001006.t003
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was made by the IVI to Shantha Biotechnics in India where it is
now licensed (ShancholH). This modified vaccine with higher
antigenic content than the previous versions has been found to be
safe and protective in India [28] and resulted in comparable
vibriocidal immune responses after one or two doses of the vaccine
raising the possibility that it may be used as a single dose, which
would greatly simplify vaccine delivery in times of outbreaks [29].
Further studies to confirm our findings are necessary; however,
these results provide hope that the vaccine will be used not only for
endemic cholera control but in times of outbreaks as well, when
mortality may be higher [30].
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